Plain-English translation of NCT05612594 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether a medication called bexagliflozin can help reduce sleep apnea — a condition where breathing repeatedly stops and starts during sleep. The medication is being tested in people who are overweight or obese and have moderate to severe sleep apnea. Researchers believe this treatment might work by reducing fat buildup in areas that narrow the airway, which could help you breathe better at night.
Sleep apnea is common in people with excess weight, and current treatments don't work well for everyone. This medication is being tested because it may help reduce the fatty tissue that blocks airways during sleep, potentially offering a new treatment option beyond current standard care.
You likely qualify if…
You likely don't qualify if…
You will take either the study medication or a placebo (a pill with no active ingredient) once daily for 6 months, alongside your regular sleep apnea care. At the start and end of the study, you'll have MRI scans to measure fat tissue and airway size, complete a sleep test to measure your breathing during sleep, have your neck measured, and provide blood samples. The entire study lasts about 6 months.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States